Alhemo

Alhemo is a preventive injection for people with hemophilia A or B with inhibitors, aged 12 and above. It helps reduce and prevent bleeding episodes by regulating the clotting pathway.

Molecule Details :

  • Molecule Name :

    Concizumab-Mtci
  • Innovator :

    NOVO NORDISK INC
  • Approval Date :

    20-Dec-24
  • Data Exclusivity Expiry :

    20-Dec-28
  • Market Exclusivity Expiry :

    20-Dec-36
  • Dosage Form :

    Subcutenous Injection
  • Strength :

    60MG/1.5ML, 150MG/1.5ML and 300MG/3ML
  • Therapeutic Category :

    Hemostatic Agents
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    56
  • 2026 :

    100
  • 2027 :

    145
  • 2028 :

    191
  • 2029 :

    212
  • 2030 :

    226
  • 2031 :

    247
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?